BioCity based Sygnature Discovery, a world-leading integrated drug discovery and non-clinical solutions provider, has begun expanding into new state of the art laboratories at Bruntwood SciTech’s Alderley Park, Cheshire, adding Chemistry and Biology expertise to its DMPK and Translational Oncology teams already present on the...
BioCity, Nottingham based Sygnature Discovery, a world-leading integrated discovery and non-clinical solutions provider based in the UK, has joined forces with Altasciences, a CRO/CDMO in the U.S. and Canada specializing in a flexible, innovative approach to comprehensive early stage drug development, to deliver a series...
Sygnature invests in new capabilities at two of its laboratories. • Automated sample storage for multi-customer, multi-year storage HTS relationships • Flow cytometry at Alderley Park to support ex vivo and in vivo tumour analysis BioCity based Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical...
Over 190 individuals from across the Healthcare and Life Sciences sector came together online, on Thursday 8 October to celebrate success at the Medilink UK National Awards. The awards recognised a multitude of achievements and outstanding contributions to the Life Sciences industry, and five companies from...
XenoGesis has been acquired by leading drug discovery CRO, Sygnature Discovery, strengthening the combined DMPK offering and enhancing existing capabilities and expertise. This latest acquisition by Sygnature serves to meet the increasing demand for DMPK services and boosts the company’s reach into the pre-clinical space. XenoGesis’ novel...
BioCity, Nottingham based Sygnature Discovery, a world-leading integrated discovery and pre-clinical solutions provider, has appointed Dr Andy Mead as Director and Head of Drug Abuse and Substance Use Disorders at its integrated in vivo pharmacology company, RenaSci. With 25 years’ experience in the science of...
Great news, at BioCity based Sygnature Discovery we’re further strengthening our oncology and immuno-oncology capabilities with the acquisition of Alderley Oncology, a focused in vivo pharmacology service provider which undertakes high quality in vivo services for cancer drug discovery. The acquisition will add significant in-house expertise at Sygnature in...
One of Nottingham’s most successful bioscience companies is working towards developing a drug to help treat the deadly coronavirus. Sygnature Discovery, which moved into BioCity in Nottingham city centre in 2004, provides drug discovery and pre-clinical services and expertise to clients across the world. The company has more than...
Pictured L-R: Dr Sharon Cheetham, Director and Dr Wioletta Pijacka, Study Director Leading in vivo pharmacology and consultancy services firm RenaSci, part of the Sygnature Group, have bolstered their Kidney Disease and Fibrosis capabilities with the appointment of Dr Wioletta Pijacka. Wioletta is an in vivo...
Friday 06 December, Nottingham, England UK. At a black-tie event held in Nottingham last night, 200 leading names and rising stars of the life sciences came together at the Medilink East Midlands Business Awards 2019. A celebration of innovation within the region, a total of seven...